Technology | FFR Technologies | May 22, 2018

FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR

Software for non-invasively assessing vessel fractional flow reserve achieves FDA 510(k) market clearance

FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR

May 22 2018 — Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for vessel Fractional Flow Reserve) software will be presented during EuroPCR 2018, May 22-25 in Paris, France. This software, which has received U.S. Food and Drug Administration (FDA) 510(k) clearance, can calculate the pressure drop and vFFR value in the coronary artery non-invasively, which means there is no need for a pressure wire and hyperemic agent.

FFR is an established technique used in interventional cardiology to measure pressure differences across a coronary stenosis. Based on this, cardiologists may take a decision on whether a coronary stenosis has to be treated with angioplasty or not. This examination is done during a catheterization procedure with the support of costly pressure wires and hyperemic agents.

CAAS vFFR allows clinicians to use two standard angiograms taken during a catheterization procedure as input to get access to coronary physiology assessment. For percutaneous coronary interventions (PCI), within one easy workflow, CAAS vFFR offers a combination of functional and anatomical lesion assessment (such as percentage stenosis) to support the interventional cardiologist in the clinical decision making process.

The FAST study — led by Ken Masdjedi, M.D., and Joost Daemen M.D., Ph.D., from Erasmus Medical Center, Rotterdam, the Netherlands — shows that vFFR as calculated using CAAS vFFR has a high linear correlation to invasively measured FFR.

"In the FAST study, we demonstrated that vFFR as calculated using CAAS vFFR has a high linear correlation to invasively measured FFR and high diagnostic accuracy to detect FFR less than or equal to 0.80. vFFR is a promising, fast and easy to use tool to assess coronary physiology without the need for a costly pressure wire or hyperemic agent,” said Daemen, principal investigator.

CAAS vFFR is CE marked in Europe and PMDA-cleared in Japan.

For more information: www.piemedicalimaging.com

 

Related Content

News | Angiography

April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips ...

Home April 07, 2021
Home
Feature | Angiography | By Bhvita Jani

January 19, 2021 – With the postponement of non-essential elective surgeries and medical procedures in 2020 to conserve ...

Home January 19, 2021
Home
News | Angiography

December 3, 2020 — GE Healthcare is introducing a new version of its robotic driven angiography system for image guided ...

Home December 01, 2020
Home
Feature | Angiography | Dave Fornell, Editor

Philips is working on a prototype cath lab angiographic imaging system that might be able to replace the current X-ray ...

Home March 12, 2020
Home
News | Angiography

February 12, 2020 — The University of Wisconsin (UW) Health’s University Hospital in Madison, Wis., recently became the ...

Home February 12, 2020
Home
News | Angiography

October 9, 2019 — In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-date ...

Home October 09, 2019
Home
Technology | Angiography

September 17, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of ...

Home September 17, 2019
Home
News | Angiography

August 21, 2019 — Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac ...

Home August 21, 2019
Home
Technology | Angiography

June 24, 2019 — Siemens Healthineers and Mentice AB announced the collaboration to fully integrate Mentice’s VIST ...

Home June 24, 2019
Home
Technology | Angiography

June 4, 2019 — Medis Medical Imaging Systems B.V. has received clearance from the U.S. Food and Drug Administration for ...

Home June 04, 2019
Home
Subscribe Now